Skip to main content
Stem Cell Research & Therapy logoLink to Stem Cell Research & Therapy
. 2019 Jan 21;10:33. doi: 10.1186/s13287-019-1132-1

Correction to: Human umbilical cord-derived mesenchymal stem cells protect against experimental colitis via CD5+ B regulatory cells

Kang Chao 1,2, Shenghong Zhang 1, Yun Qiu 1, Xiaoyong Chen 3, Xiaoran Zhang 3, Chuang Cai 3, Yanwen Peng 3, Ren Mao 1, Meirav Pevsner-Fischer 4, Shomron Ben-horin 1, Eran Elinav 4, Zhirong Zeng 1, Baili Chen 1, Yao He 1, Andy Peng Xiang 3, Minhu Chen 1,
PMCID: PMC6341599  PMID: 30665468

Correction to: Stem Cell Res Ther

https://doi.org/10.1186/s13287-016-0376-2

The original article [1] contains a duplication error within Fig. 3. The correct version of Fig. 3 can instead be viewed directly ahead.

Fig. 3.

Fig. 3

hUC-MSCs alter numbers of regulatory T cells (Tregs) in colitis mice. Lymphocytes were co-stained with anti-CD4 and anti-FoxP3 antibodies and evaluated by flow cytometry. Tregs were defined as CD4+FoxP3+. The frequency of Tregs from the hUC-MSC-treated group was significantly lower than that in controls. Representative dot plots of Tregs in the spleen (a) and mesenteric lymph node (MLN) (c) of each group. Treg proportions are shown in (b) and (d). Data are presented as plots with P value. n = 9 for each group; * P < 0.05 vs. MSC-treated mice. hUC-MSC human umbilical cord-derived mesenchymal stem cell, TNBS trinitrobenzenesulfonic acid

Reference

  • 1.Chao K, et al. Human umbilical cord-derived mesenchymal stem cells protect against experimental colitis via CD5+ B regulatory cells. Stem Cell Res Ther. 2017;7:109. doi: 10.1186/s13287-016-0376-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Stem Cell Research & Therapy are provided here courtesy of BMC

RESOURCES